Logo image of AQST

AQUESTIVE THERAPEUTICS INC (AQST) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AQST - US03843E1047 - Common Stock

5.935 USD
-0.04 (-0.59%)
Last: 12/26/2025, 2:22:48 PM
Fundamental Rating

2

Overall AQST gets a fundamental rating of 2 out of 10. We evaluated AQST against 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AQST have multiple concerns. While showing a medium growth rate, AQST is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AQST has reported negative net income.
In the past year AQST has reported a negative cash flow from operations.
AQST had negative earnings in each of the past 5 years.
In the past 5 years AQST always reported negative operating cash flow.
AQST Yearly Net Income VS EBIT VS OCF VS FCFAQST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

AQST's Return On Assets of -42.14% is in line compared to the rest of the industry. AQST outperforms 42.19% of its industry peers.
Industry RankSector Rank
ROA -42.14%
ROE N/A
ROIC N/A
ROA(3y)-50.85%
ROA(5y)-71.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AQST Yearly ROA, ROE, ROICAQST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

1.3 Margins

The Gross Margin of AQST (60.28%) is better than 69.27% of its industry peers.
AQST's Gross Margin has improved in the last couple of years.
AQST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y2.38%
AQST Yearly Profit, Operating, Gross MarginsAQST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

AQST does not have a ROIC to compare to the WACC, probably because it is not profitable.
AQST has more shares outstanding than it did 1 year ago.
AQST has more shares outstanding than it did 5 years ago.
AQST has a better debt/assets ratio than last year.
AQST Yearly Shares OutstandingAQST Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AQST Yearly Total Debt VS Total AssetsAQST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

AQST has an Altman-Z score of -0.89. This is a bad value and indicates that AQST is not financially healthy and even has some risk of bankruptcy.
AQST's Altman-Z score of -0.89 is in line compared to the rest of the industry. AQST outperforms 44.27% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.89
ROIC/WACCN/A
WACC9.91%
AQST Yearly LT Debt VS Equity VS FCFAQST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

AQST has a Current Ratio of 5.93. This indicates that AQST is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.93, AQST is in the better half of the industry, outperforming 68.75% of the companies in the same industry.
A Quick Ratio of 5.62 indicates that AQST has no problem at all paying its short term obligations.
AQST has a better Quick ratio (5.62) than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 5.93
Quick Ratio 5.62
AQST Yearly Current Assets VS Current LiabilitesAQST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

AQST shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -61.36%.
The Revenue for AQST has decreased by -26.32% in the past year. This is quite bad
The Revenue has been growing slightly by 1.82% on average over the past years.
EPS 1Y (TTM)-61.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.69%
Revenue 1Y (TTM)-26.32%
Revenue growth 3Y4.23%
Revenue growth 5Y1.82%
Sales Q2Q%-5.43%

3.2 Future

Based on estimates for the next years, AQST will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.25% on average per year.
The Revenue is expected to grow by 32.47% on average over the next years. This is a very strong growth
EPS Next Y-26.41%
EPS Next 2Y-2.56%
EPS Next 3Y21.07%
EPS Next 5Y19.25%
Revenue Next Year-23.61%
Revenue Next 2Y8%
Revenue Next 3Y26.42%
Revenue Next 5Y32.47%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AQST Yearly Revenue VS EstimatesAQST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
AQST Yearly EPS VS EstimatesAQST Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -0.5 -1 -1.5 -2 -2.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AQST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AQST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AQST Price Earnings VS Forward Price EarningsAQST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AQST Per share dataAQST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

AQST's earnings are expected to grow with 21.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.56%
EPS Next 3Y21.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AQST!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

AQUESTIVE THERAPEUTICS INC

NASDAQ:AQST (12/26/2025, 2:22:48 PM)

5.935

-0.04 (-0.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-03 2026-03-03/amc
Inst Owners53.3%
Inst Owner Change25.57%
Ins Owners4.49%
Ins Owner Change-0.93%
Market Cap724.07M
Revenue(TTM)43.40M
Net Income(TTM)-68.92M
Analysts83.75
Price Target10.51 (77.09%)
Short Float %17.65%
Short Ratio6.91
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.44%
Min EPS beat(2)-3.59%
Max EPS beat(2)18.46%
EPS beat(4)1
Avg EPS beat(4)-15.2%
Min EPS beat(4)-38.41%
Max EPS beat(4)18.46%
EPS beat(8)2
Avg EPS beat(8)-15.3%
EPS beat(12)6
Avg EPS beat(12)0.72%
EPS beat(16)10
Avg EPS beat(16)5.11%
Revenue beat(2)0
Avg Revenue beat(2)-8.18%
Min Revenue beat(2)-13.36%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-16.45%
Min Revenue beat(4)-30.1%
Max Revenue beat(4)-2.99%
Revenue beat(8)2
Avg Revenue beat(8)-1.61%
Revenue beat(12)5
Avg Revenue beat(12)1.04%
Revenue beat(16)9
Avg Revenue beat(16)4.52%
PT rev (1m)14.8%
PT rev (3m)17.38%
EPS NQ rev (1m)-2.06%
EPS NQ rev (3m)4.98%
EPS NY rev (1m)0.17%
EPS NY rev (3m)9.23%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-1.53%
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)-0.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.68
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.71
EYN/A
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.36
BVpS-0.03
TBVpS-0.03
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.14%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.28%
FCFM N/A
ROA(3y)-50.85%
ROA(5y)-71.01%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y2.38%
F-Score2
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.5%
Cap/Sales 1.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.93
Quick Ratio 5.62
Altman-Z -0.89
F-Score2
WACC9.91%
ROIC/WACCN/A
Cap/Depr(3y)67.19%
Cap/Depr(5y)49.48%
Cap/Sales(3y)2.51%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-61.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.69%
EPS Next Y-26.41%
EPS Next 2Y-2.56%
EPS Next 3Y21.07%
EPS Next 5Y19.25%
Revenue 1Y (TTM)-26.32%
Revenue growth 3Y4.23%
Revenue growth 5Y1.82%
Sales Q2Q%-5.43%
Revenue Next Year-23.61%
Revenue Next 2Y8%
Revenue Next 3Y26.42%
Revenue Next 5Y32.47%
EBIT growth 1Y-166.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-84.03%
EBIT Next 3Y24.61%
EBIT Next 5Y38.19%
FCF growth 1Y-956.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-827%
OCF growth 3YN/A
OCF growth 5YN/A

AQUESTIVE THERAPEUTICS INC / AQST FAQ

What is the fundamental rating for AQST stock?

ChartMill assigns a fundamental rating of 2 / 10 to AQST.


Can you provide the valuation status for AQUESTIVE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to AQUESTIVE THERAPEUTICS INC (AQST). This can be considered as Overvalued.


How profitable is AQUESTIVE THERAPEUTICS INC (AQST) stock?

AQUESTIVE THERAPEUTICS INC (AQST) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for AQST stock?

The Earnings per Share (EPS) of AQUESTIVE THERAPEUTICS INC (AQST) is expected to decline by -26.41% in the next year.